SELLAS Life Sciences (SLS) Total Non-Current Liabilities (2010 - 2022)

SELLAS Life Sciences (SLS) has 13 years of Total Non-Current Liabilities data on file, last reported at $16.1 million in Q4 2022.

• On a quarterly basis, Total Non-Current Liabilities rose 185.72% year-over-year to $16.1 million in Q4 2022; TTM through Dec 2022 was $16.1 million, a 185.72% increase from a year earlier, with the FY2022 full-year figure at $16.1 million, up 185.72% from the prior year.
• Total Non-Current Liabilities for Q4 2022 stood at $16.1 million, up from $13.2 million in the prior quarter.
• Over the last five years, Total Non-Current Liabilities for SLS reached as high as $30.1 million in Q1 2018 and fell as low as $3.9 million in Q1 2020.
• Historically, Total Non-Current Liabilities has averaged $10.9 million across 5 years, with a median of $7.2 million in 2019.
• Across the five-year window, Total Non-Current Liabilities plunged 79.9% in 2019 and surged 185.72% in 2022, its largest moves.
• Year by year, Total Non-Current Liabilities stood at $7.3 million in 2018, then fell by 23.69% to $5.6 million in 2019, then soared by 140.1% to $13.5 million in 2020, then sank by 58.14% to $5.6 million in 2021, then soared by 185.72% to $16.1 million in 2022.
• Per Business Quant data, the three most recent Total Non-Current Liabilities figures were $16.1 million in Q4 2022, $13.2 million in Q3 2022, and $13.0 million in Q2 2022.